First-Cycle Adduct Flag for Pediatric Cisplatin Hearing Protection

A pediatric oncology blood test that flags, within 24 hours of a child's first cisplatin dose, which patients are forming unusually high DNA adduct levels, so clinicians can intensify hearing protection, monitoring, or switch drugs before permanent hearing loss accumulates.